Jpmorgan Chase & CO Sensei Biotherapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Sensei Biotherapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 748 shares of SNSE stock, worth $418. This represents 0.0% of its overall portfolio holdings.
Number of Shares
748
Previous 668
11.98%
Holding current value
$418
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding SNSE
# of Institutions
26Shares Held
2.12MCall Options Held
0Put Options Held
0-
Ikarian Capital, LLC Dallas, TX650KShares$364,0000.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA619KShares$346,5030.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny224KShares$125,3190.0% of portfolio
-
Boothbay Fund Management, LLC New York, NY173KShares$96,7870.0% of portfolio
-
Geode Capital Management, LLC Boston, MA163KShares$91,3570.0% of portfolio
About Sensei Biotherapeutics, Inc.
- Ticker SNSE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,720,300
- Market Cap $17.2M
- Description
- Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...